IFNB1 and myeloid sarcoma: Specifically, through a pharmacogenetic approach, we identified an association between rs7298096, located in an enhancer region ~3.3 kb upstream of the NINJ2 gene and associated with its expression [6], and the long-term response to IFN-β treatment in MS patients (rs7298096A: OR = 1.96, p = 9.81 × 10−5) [7].